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Abstract: Despite their clinical significance and substantial human health burden, fungal infections
remain relatively under-appreciated. The widespread overuse of antibiotics and the increasing
requirement for indwelling medical devices provides an opportunistic potential for the overgrowth
and colonization of pathogenic Candida species on both biological and inert substrates. Indeed, it is
now widely recognized that biofilms are a highly important part of their virulence repertoire.
Candida albicans is regarded as the primary fungal biofilm forming species, yet there is also
increasing interest and growing body of evidence for non-Candida albicans species (NCAS) biofilms,
and interkingdom biofilm interactions. C. albicans biofilms are heterogeneous structures by definition,
existing as three-dimensional populations of yeast, pseudo-hyphae, and hyphae, embedded within a
self-produced extracellular matrix. Classical molecular approaches, driven by extensive studies
of laboratory strains and mutants, have enhanced our knowledge and understanding of how
these complex communities develop, thrive, and cause host-mediated damage. Yet our clinical
observations tell a different story, with differential patient responses potentially due to inherent
biological heterogeneity from specific clinical isolates associated with their infections. This review
explores some of the recent advances made in an attempt to explore the importance of working with
clinical isolates, and what this has taught us.
Keywords: Candida; biofilm; antifungal
1. What Is Biofilm Heterogeneity?
Classical molecular microbiological approaches suggest that deletion or over expression of
particular genes enables us to definitively deduce their function. Reinforced by structural biology
studies, these tactics allow us to deduce the structure/function of particular proteins within the context
of a microbes pathogenic ability. Nevertheless, this assumes that molecular manipulations do not have
any pleiotropic effects, nor does this take into account inherent biological heterogeneity that bears
itself amongst a range of clinical isolates (Figure 1). This begs the question whether using laboratory
strains is the optimal way in developing our understanding of microbial pathogenesis [1], or instead,
whether taking a combinatory approach through evaluating phenotypic and genotypic characteristics
of clinical isolates would enhance our understanding. This review focuses on Candida biofilms and
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attempts to examine the literature with respect to what insights can be garnered from working with
clinical isolates and observing the inherent heterogeneity that exists.
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Figure 1. Factors influencing biofilm formation. There are multiple stimuli that can induce biofilm 
formation including the immune response, antifungal stress, and bacterial derived metabolites. 
Environmental stressors can also stimulate biofilm formation, and these include the availability of 
nutrients, temperature, and pH. Dashed arrows represent different factors that associate with biofilm 
formation. 
2. How Do We Investigate Biofilm Formation? 
The key driver in understanding and evaluating biofilm formation from important Candida 
species lies in the quantitative methods utilized. When screening large collections of clinical isolates 
from different patient cohorts, several experimental strategies have been utilized, predominantly 
quantifying biomass using dry weight, stains such as crystal violet, and the metabolic dye XTT [2]. 
Each technique has their own benefits and caveats, but caution must be taken when interpreting the 
data achieved from each assay, particularly when correlating it to clinical outcomes. Given the 
heterogeneity found between strains, alongside varying laboratory models and techniques, 
standardization becomes problematic. For example, two of the most commonly used media for 
biofilm formation are Roswell Park Memorial Institute (RPMI) media and Spider media. Studies have 
identified that RPMI is more supportive of biofilm formation, stimulating biofilms that are three 
times thicker than Spider media [3]. Furthermore, these media are not physiologically relevant, with 
several studies employing more biologically relevant conditions for biofilm formation through use 
of artificial saliva, urine, and mammalian serum [4–6]. One of the most commonly used bioassays is 
the sodium salt XTT (2,3-bis(2-methoxy-4-nitro-5-sulfo-phenyl)-2H-tetrazolium-5-carboxanilide) 
[7,8]. This biofilm assay is highly reproducible and allows for a high throughput of multiple 
microtiter plates without compromising accuracy. Its usefulness comes with susceptibility testing, 
allowing for the direct comparison of antifungal treated samples compared to an untreated control 
[9]. Given the metabolic variation observed between both different strains and species, caution must 
be taken when interpreting the assay, as a measurement for biofilm development may simply be a 
reflection of high cell numbers [10,11]. For example, scant biofilms of non-albicans yeasts may show 
a high XTT value, yet minimal biomass is present. Therefore, the output achieved from XTT is only 
cellular viability and it does not take into account other biofilm components such as the extracellular 
matrix (ECM), which are arguably the most important when it comes to biofilms [12]. 
Another commonly used assay for biofilm formation is crystal violet staining. This method 
provides the total quantification of the biofilm biomass (cells and ECM) and also allows for rapid, 
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Another commonly used assay for biofilm formation is crystal violet staining. This method
provides the total quantification of the biofilm biomass (cells and ECM) and also allows for rapid,
high-throughput processing of multiple samples. However, variability of the washing step can result
in both over- and under-estimation of biomass, with the assay also unable to differentiate subtle
differences between samples [2]. An interesting example of this was described in a recent study,
where these techniques were used to stratify the ability of Candida bloodstream isolates to form
biofilms [13]. There was no evident standard for their stratification to denote strains as biofilm or
non-biofilm formers, with a crystal violet values of OD570 > 0.09 simply denoted as a biofilm former.
By doing so, it was concluded that non-Candida albicans species (NCAS) form greater biofilms than
C. albicans, and that biofilm formation does not correlate to clinical outcomes. This is contrary to a
wealth of previous literature, whereby the ability of Candida isolates to form a biofilm does associate
with mortality [14–17].
Discrepancies between these findings illustrates the necessity for standardised testing to elucidate
biofilm-related risk factors. Our group has taken a “belt and braces” approach, using a combinational
approach of crystal violet, XTT, and SYTO®9 fluorescence quantitative biofilm assays (Thermo Fisher
Scientific, Paisley, UK). Here, significant correlations were observed for C. albicans biofilm formation,
which was subsequently used to stratify biofilm-forming ability [14]. Irrespective of the particular
quantitative approach, wide-spread biofilm heterogeneity is observed within different clinical panels of
isolates [13,14,18,19]. Collectively, these data suggest that different Candida strains function differently,
and that consideration should be given to the individual isolates as we try and understand their clinical
importance with respect to antifungal resistance and pathogenic potential.
3. Is Heterogeneity Clinically Important?
Since the earliest descriptions of Candida biofilms, great strides have been made to unequivocally
demonstrate their clinical significance, despite perceived contention in the field. Throughout the human
host, Candida biofilms colonize a wide variety of anatomical locations, as shown in Table 1. The oral
and vaginal epithelium provide a mucosal niche for biofilm formation, whilst indwelling medical
devices such as prosthetic heart valves and central venous catheters provide an inert, abiotic substrate
for subsequent biofilm adherence and proliferation [20,21]. Irrespective of isolation site, biofilm
heterogeneity has been reported, including the oral cavity, bloodstream, and urinary tract [14,22–26].
Table 1. Mucosal and medical-devices associated Candida biofilm infections.
Location Fungi Bacteria Reference
Mucosal
Oral cavity C. albicans, C. glabrata Streptococcus mutans, Streptococcus gordonii,Porphomonas gingivalis, Staphylococcus aureus [27–31]
Respiratory tract C. albicans Pseudomonas aeruginosa [32,33]
Gastrointestinal tract C. albicans Enterococcus faecalis, Clostridium difficle [34,35]
Vagina C. albicans Lactobacillus spp. [36]
Wounds C. albicans, C. auris Pseudomonas aeruginosa, Staphylococcus aureus [37,38]
Device-related
Denture C. albicans, C. glabrata Lactobacillus spp. [39,40]
Voice prosthesis C. albicans, C. tropicalis Rothia dentocariosa [41,42]
Artificial heart valves C. albicans Staphylococcus aureus, Staphylococcus epidermidis [43,44]
Vascular catheter C. albicans, C. auris Staphylococcus aureus, Staphylococcus epidermidis [45–47]
Urinary catheter C. albicans, C. auris Escherichia coli [48,49]
Within a clinical setting, intravascular catheters provide an optimal environment for Candida spp.,
allowing for the development and maturation of biofilms to which cells can disperse and subsequently
cause candidaemia. Dispersed biofilm cells have been shown to be more pathogenic than their
planktonic counterparts, exhibiting greater cytotoxicity and virulence in vivo [50]. Therefore, the
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role of the biofilm phenotype has potentially profound implications within the clinical environment.
An initial study from Tumbarello and colleagues (2007) [17] aimed to identify the top risk factors
associated with mortality rates in candidaemia patients. Using multivariate analysis, they were able
to distinguish inadequate antifungal therapy (odds ratio (OR) 2.36, p = 0.03), APACHE III (OR 1.03,
p < 0.001), and overall biofilm-forming Candida species (OR 2.33, p < 0.007) as significant variables
associated with mortality [17]. When scrutinized at the Candida species level, only C. albicans (OR 3.97,
p < 0.001) and C. parapsilosis (OR 4.16, p = 0.03) were shown to significantly correlate to biofilm-based
mortality. A follow up study subsequently identified that central venous and urinary catheters, use
of total parenteral nutrition, and diabetes mellitus as independent entities of bloodstream infections
caused by biofilm forming isolates [16]. Furthermore, they demonstrated the potential economic
burden of these isolates resulting from increased lengths of hospital stays and use of antifungals and
ultimately resulted in an increased possibility of mortality [16]. A more recent, prospective analysis
subsequently identified line removal (p = 0.032) as a significant risk factor associated with mortality
rates from a candidaemia patient cohort, with the removal of an indwelling line correlating with
a more positive patient outcome [14]. Interestingly, when this was then subsequently assessed at
Candida species level, survival analysis demonstrated significantly higher survival rates for patients
with C. albicans associated line removal compared to no removal, with no differences observed in
NCAS [51]. Furthermore, Tascini and colleagues used a random forest model of analysis to cluster
candidaemia associated mortality and to identify its accompanying risk factors [52]. It was shown
that azole use and high APACHE II, as well as biofilm formation, significantly correlated with the
highest mortality group [52]. Published guidelines have suggested that catheter-related bloodstream
infections should result in the direct removal of such devices, if possible [53–55]. Furthermore, a
meta-analysis of seven clinical trials revealed that the removal of central venous catheters significantly
correlated with reduced mortality rates (OR 0.50, p < 0.001) [56]. Conversely, a study assessed the
efficacy of catheter removal within 24 h to 48 h of antifungal therapy and demonstrated no clinical
improvement. This study, however, looked at echinocandins and liposomal amphotericin B, two
highly active Candida biofilm agents [57]. What these studies do provide is an insight into differential
responses to biofilm-active therapies, and suggest clinical isolates respond differently depending on
their capacities to form biofilms. Despite the majority of studies focusing on the potential for Candida
biofilms to develop on hard, abiotic surfaces, there are a variety of mucosal niches within the host to
which Candida can colonise as a biofilm an induce tissue damage.
Key to successful colonisation and host damage to a mucosal niche is the secretion of
various hydrolytic enzymes. These secreted proteins are a primary attribute within the virulence
armamentarium of the organism allowing it to invade host tissue, and include proteinases, haemolysins,
and phospholipase. Of these enzymes, the secreted aspartyl proteinases (Saps) are the most studied,
comprising a family of ten genes (SAP1–10). The secretion of these enzymes has been attributed
with disease, with high levels of expression observed from a variety of diseases including infections
of the bloodstream, vagina, oral cavity, and diabetes mellitus [58–60]. Given the diversity of the
Sap family, then differential expression of independent genes has been associated with varying
anatomical location [59,61]. During biofilm formation, SAP5 is up-regulated, significantly correlating
with biomass [19]. Indeed, an integrated global substrate and proteomics approach identified SAP5
and SAP6 as the major biofilm-related proteases utilised by C. albicans. Manipulation of both of these
genes resulted in decreased adhesion and impaired biofilm development both in vitro and in vivo,
highlighting their role as potential biofilm biomarkers [62]. Recent studies have identified a novel
fungal toxin termed candidalysin, a hyphae-specific peptide critical for epithelial damage [63] and
expression of the gene coding this toxin (ECE1) was shown to be highly up-regulated in C. albicans
isolates capable of forming biofilms [64].
An area worthy of consideration for mucosal biofilm formation is vulvovaginal candidiasis (VVC).
Although not life-threatening per se, this infection will affect up to 75% of women in their lives at
least once and are one of the most common fungal infections globally [65]. While the majority of
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these cases are sporadic and will clear after one episode, some women will emerge with persistent
occurrences (>4 episodes a year), despite being completely asymptomatic between these episodes
(recurrent VVC (RVVC)) [66]. The reasoning for RVVC is multi-factorial, yet given that azoles are first
line topical drug of choice and have widespread availability from over the counter, then inadequate
therapy is extremely problematic. While biofilm formation is regarded as a pathogenic attribute of
bacterial vaginosis, its role in RVVC remains equivocal, despite a growing body of evidence to suggest
otherwise [23,67–69]. Candida biofilms have been shown to form on the vaginal mucosa in vivo, as well
as on inert substrates such as intrauterine contraceptive devices [67,70]. A recent study from our
group screened a cohort of 300 VVC isolates for their epidemiology, biofilm formation, and azole
susceptibility [23]. Interestingly, an epidemiological shift towards NCAS was observed, and that biofilm
formation was heterogeneous between these isolates regardless of Candida species. For C. albicans,
it was demonstrated that the planktonic MIC50 for fluconazole was 4 mg/L, yet when the susceptibility
profile of these isolates was tested as biofilms, the MIC50 escalated to >32 mg/L. This highlights the
role for the biofilm phenotype, and may go towards explaining the chronic phenotype in this patient
cohort and irresponsiveness to treatment.
4. How Does Heterogeneity Impact Antifungal Treatment?
Antifungal resistance is a complex, multifactorial process to which can be induced in response
to a compound or as an irreversible genetic alteration as a result of prolonged drug exposure.
While resistant planktonic cells predominantly arise from inherited traits to maintain a resistant
phenotype, biofilm resistance rises through mechanisms such as over-expression of target molecules,
efflux pump activity, and through the protective barrier of the extracellular matrix (ECM) allowing
limited diffusion. Undoubtedly, the most defining characteristic of biofilms is this intrinsic and
adaptive recalcitrance to many antimicrobial therapies. Compared to their free-floating planktonic
equivalents, up to 1000-fold higher concentrations of antifungal agents can be required to effectively
kill Candida biofilms in vitro, with the same decreased sensitivities also observed in vivo [71,72].
Several clinical observations have associated the ability to form biofilms with mortality, but also
with azole and inadequate antifungal use. Many studies have sub-categorised C. albicans isolates
as low biofilm formers (LBF) and high biofilm formers (HBF) [14,73,74]. Phenotypically, biofilms
formed by these isolates are distinct, with LBF existing predominantly as sparse populations of
yeast cells and pseudohyphae, whereas HBF have a dense, tenacious hyphae based morphology
(Figure 2). In vivo, there is also biological differences, with increased mortality rates observed in
HBF compared to LBF [19,75]. Additionally, it was shown in vitro that isolates categorised as LBF
and HBF were differentially sensitive to azoles and echinocandins at both low and high dosage,
with the later less susceptible to these concentrations [14]. Furthermore, HBF are less responsive to
amphotericin B therapy, with an eight-fold increase in concentration needed to achieve an 80% kill in
this population [19].
Prolonged and inadequate antifungal exposure has resulted in the emergence of both azole
and echinocandin resistant strains [76,77]. Partly responsible for this problem is the occurrence of
heteroresistance (HR), a phenomenon described in both prokaryotic and eukaryotic pathogens [78–80].
HR is defined as sub-populations of cells existing within a primarily susceptible population, able to
survive antimicrobial challenge higher than the strains given minimum inhibitory concentration.
These cells are unidentifiable from within this population using standard broth microdilution
assays [81]. Furthermore, it has repercussions of inadequate antifungal therapy, resulting in ineffective
patient management and potential chronic infection. The potential role of HR in biofilms remains
unclear, yet given that HR has been shown to significantly correlate with the upregulation of efflux
membrane transporters [78], a key azole resistance mechanism of Candida biofilms [82,83], then it is
highly plausible that they may occur within biofilm communities.
Another theory that yields to heterogeneous drug tolerant sub-populations are persister cells.
While they have been extensively characterised within bacterial pathogens [84], their role in
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Candida is less well defined. Persister cells are described as a population of dormant cells,
heterogeneously populated throughout a biofilm that remain tolerant to antimicrobial therapy [84].
Despite demonstrating similar recalcitrant phenotypes, there remains fundamental differences between
persister and HR cells. Persister cells display phenotypic differences yet remain genetically identical to
the remainder of their population [85]; this is unlike HR, whereby genetic alteration as a consequence
of aneuploidy may potentially play a role in these drug tolerant phenotypes. However, it has been
demonstrated that diploid biofilms contain 10 times the number of persister cells within a population,
compared to haploid biofilms. Interestingly, overexpression of AHP1 in the haploid genotype restored
the persister cell population [86]. Furthermore, the active mechanism of persister cells remains
unknown, yet has been shown not to be linked to efflux pumps [87], whereas HR levels have been
shown to correlate to efflux pump activity [78]. In Saccharomyces cerevisiae, the TORC1 pathway is
involved in promoting amphotericin B persistence, with inhibition of this pathway also increasing the
quantity of persisters in C. albicans and C. glabrata [88]. A proteomics approach was taken to characterise
C. albicans biofilm persister cells following exposure to high amphotericin B treatment [89]. These cells
were shown to have a unique profile, displaying 205 differently expressed proteins. Interestingly,
the up-regulation of the stress response from the heat shock protein (HSP) family was identified,
including HSP90, a key regulator of biofilm dispersion and drug resistance [90]. While there have
only been a limited number of studies in fungal biofilms with respect to peristers, predominantly
focusing on C. albicans, they are also studies in a number of NCAS, including C. krusei, C. parapsilosis,
and C. glabrata [88,91,92].
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Figure 2. Differential biofilm formation of Candida species. Scanning electron micrograph (SEM) of C. 
albicans low biofilm formers (LBF) (A) existing as mainly yeast cells and pseudo-hyphae, compared 
to the hyper-filamentous morphology of the high biofilm formers (HBF) (B); Micrograph of C. glabrata 
biofilm sparsely populating the surface (C); SEM image of a biofilm formed by an aggregating strain 
of C. auris (D). Scale bars represent 20 µm at ×1000 magnification. 
5. Do Non-Albicans Species Play a Role? 
Despite C. albicans being regarded as the principal biofilm forming pathogen of the genus, there 
has been a steady flow of research looking at non-albicans biofilms over the last decade. A recent 
study from Soldini and colleagues (2017) [15], demonstrated biofilm heterogeneity within a C. 
parapsilosis candidaemia patient group. By grouping these isolates into HBF and LBF, they identified 
that central venous catheter (CVC)-related candidaemia and a poorer patient outcome were 
significantly associated with the HBF group [15]. The clinical consequences of NCAS have also been 
described with C. glabrata being identified frequently from catheter-associated candidaemia [93]. A 
study from Silva and colleagues (2009) [94] assessed the biofilm forming ability and matrix 
composition of a panel of NCAS isolates. They showed that C. glabrata demonstrated low levels of 
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5. Do Non-Albicans Species Play a Role?
Despite C. albicans being regarded as the principal biofilm forming pathogen of the genus, there
has been a steady flow of research looking at non-albicans biofilms over the last decade. A recent study
from Soldini and colleagues (2017) [15], demonstrated biofilm heterogeneity within a C. parapsilosis
candidaemia patient group. By grouping these isolates into HBF and LBF, they identified that central
venous catheter (CVC)-related candidaemia and a poorer patient outcome were significantly associated
with the HBF group [15]. The clinical consequences of NCAS have also been described with C. glabrata
being identified frequently from catheter-associated candidaemia [93]. A study from Silva and
colleagues (2009) [94] assessed the biofilm forming ability and matrix composition of a panel of
NCAS isolates. They showed that C. glabrata demonstrated low levels of biofilm formation, whereby
little heterogeneity was observed in terms of biomass. These observations may be explained by the
lack of sensitivity in the biomass assays, being unable to detect subtle differences low-level biofilms.
In addition, both C. parapsilosis and C. tropicalis displayed generally greater biomass, with heterogeneity
observed between the isolates they tested [94]. Interestingly, C. parapsilosis and C. glabrata biofilm
ECM was predominantly composed of carbohydrate compared to C. tropicalis, to which had both
low carbohydrate and protein content [94]. The dynamics of multi-Candida spp. biofilms in response
to antifungal agents have been evaluated, showing that in the presence of other species, C. albicans
lost its compositional dominance within the biofilm in response to antifungal treatment, and that
C. glabrata and C. tropicalis demonstrated reduced susceptibility to amphotericin B when in the
mixed-species biofilm [95]. Additionally, it has been shown that C. albicans can augment the virulence
of C. glabrata with regards to its invasive capacity. As seen with numerous species of bacteria, C. glabrata
preferentially binds to the hyphal elements of C. albicans, thus enhancing its invasion of oral tissues,
analogous to injection from a needle stick [96,97].
Of recent interest in the medical mycology field is the emerging pathogen Candida auris. It has
received considerable attention due to its resistance profile, difficulty for accurate identification, and
its ability to cause hospital outbreaks. It is phylogenetically similar to C. lusitaniae and C. haemulonii,
yet there is noticeable differences compared to many other Candida spp. [98]. There has been a
simultaneous emergence of distinct clades of this organism in different geographical locations,
currently categorised into the East Asian, South Asian, South American, and South African
clades [99,100]. Between these four clades, there is extensive genetic variance, yet minimal internal
clade differences [99]. In vivo it is highly virulent, with invertebrate models demonstrating comparable
virulence to C. albicans [37,101]. Initial studies identified two distinct phenotypes between clinical
isolates, existing as either aggregates or single cellular communities. Whilst the former appears to
be generally differentially susceptible to azoles, the latter is significantly more virulent, likely due
to an inability of aggregative strains to cause disseminated infection [37]. The ability of C. auris to
form biofilms was initially disregarded [102], reporting no ability to form biofilms, although the
semi-quantitative methods used here were rudimentary. In fact, C. auris is able to form biofilms
as recently demonstrated by Sherry and colleagues (2017) [103], whereby they showed that it was
able to form intermediate levels of biomass compared to C. albicans and C. glabrata. Although these
biofilms were not comparable to C. albicans, they demonstrated a highly resistant susceptibility profile
across all classes of antifungals, most notably to echinocandins and polyenes, whereby they up to 256-
and 16-fold increases in MIC against micafungin and amphotericin B were observed, two antifungal
agents usually potent against C. albicans biofilms [103]. Further studies have identified that the
glucan synthase inhibitor SCY-078 possesses activity against C. auris biofilms, reducing the biofilm
thickness and viability, these studies did however use a 48-h treatment regimen [104]. Given the
multi-drug resistant phenotype of this organism, then its control within the nosocomial environment
is imperative. It has been shown to successfully colonise the skin [45], as well as successfully persist
on plastics and steel for prolonged periods [105,106]. Furthermore, disinfection procedures have has
variable outcomes [107], with increased concentrations and exposure times of disinfectants required to
successfully eliminate the organism [108].
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6. Interkingdom Interactions Support Biofilm Defects
Due to advances in the use of more sophisticated biofilm techniques, it is now widely appreciated
that in addition to their own clinical biofilm heterogeneity, these biofilms rarely exist as single entities.
In fact, they often exist as complex, diverse, and heterogeneous cellular communities of organisms
spanning different phylogenetic kingdoms [109]. Interactions through both a physical and chemical
nature can have negative implications for human health through the production of intensified
pathogenic phenotypes and increased tolerance to antimicrobial challenge. C. albicans is the most
common fungal pathogen frequently co-isolated from polymicrobial biofilm infections and can interact
with a number of different bacteria in a variety of ways (Table 1). While research within this field has
intensified in recent years, the majority of studies are tailored to the use of characterised laboratory
strains, with minimal focus on the impact of these interactions within clinical isolates. A study from
O’Donnell et al. (2017), observed that the increasing Candida load promoted an altered microbiome
of denture wearers [39]. The highest correlation was observed with Lactobacillus species, whereby
increased Candida burden resulted in higher abundance of Lactobacillus. This suggestive positive
relationship is conflicting to previous literature whereby an antagonistic interaction was observed [110].
Collectively this study highlights potential novel avenues of research into understanding interkingdom
interactions through the use of clinical isolates.
Chronic infections, including burn wounds and diabetic foot ulcers (DFU), are of an
increasing interest due to their economic burden and substantial contribution of morbidity and
mortality [111]. These chronic infections often comprise pathogenic, polymicrobial biofilms,
thus complicating treatment regimens [112–114]. Associated with these treatment complications
are the underappreciation of fungi as major facilitators within these communities [115]. It was recently
demonstrated in a newly developed triadic biofilm model containing C. albicans, Pseudomonas aeruginosa,
and Staphylococcus aureus [114], that single antimicrobial treatments of flucloxacillin and ciprofloxacin
were ineffective due to the fungal contingent within the biofilm [116]. Indeed, it was shown that,
in order to achieve substantial reduction in overall bioburden, an antimicrobial cocktail containing
both fungal and bacterial specific agents needed to be applied. Biofilms containing these organisms
have also been shown to be recalcitrant to disinfectant strategies, with polymicrobial biofilms showing
decreased susceptibility as compared to their single-species equivalents [117]. Collectively, these
findings highlight not only the need for accurate antifungal approaches to Candida biofilm infections but
also the appreciation of the universal fungal influence towards treatments for polymicrobial infections.
Perhaps the most well-studied mechanism of Candida–bacteria interactions is physical attachment.
A scaffold of hyphae within a biofilm provides a potential niche for the colonization of various
Gram-positive and Gram-negative bacteria, a phenomenon we have termed as a ‘mycofilm’
(Figure 3) [6]. This term is proposed through the ability of C. albicans to promote biofilm formation
of a normally biofilm defective strain of S. aureus. The bacteria preferentially adhere to hyphal as
opposed to yeast cells [118], mediated by the C. albicans agglutinin-like sequence 3 protein (Als3p) [119],
though it is likely that other reciprocal proteins are involved. Indeed, this bacterial attachment can
also be reduced through enzymatic degradation of extracellular DNA (eDNA), while concomitantly
increasing miconazole susceptibility to dual species biofilms [6]. The ECM is a defining characteristic
of these biofilms, with initial studies highlighting the protective effect of C. albicans to S. aureus
vancomycin therapy [120]. Further studies have now intricately identified fungal β-1,3-glucan as the
matrix component to which drives this resistance [121]. The authors propose a ‘barrier model’ as
the active mechanism of resistance, whereby as the biofilm matures, S. aureus becomes coated in the
secreted fungal matrix constituents thus impeding the activity of vancomycin. Interestingly, this same
component has been shown to promote fungal-derived ofloxacin tolerance in an Escherichia coli and
C. albicans dual-species biofilm [122].
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Figure 3. Candida albicans and Staphylococcus aureus dual-species biofil . Confocal laser scanning
micrograph (CLS ) (A) and scanning electron micrograph (SEM) (B) highlighting the close interaction
between the bacteria (red) and fungal hyphae (white). The C. albicans mycofilm acts as a scaffold for
S. aureus colonisation and biofilm formation. Images are viewed at ×2000 magnification.
A less well-studied mechanism within polymicrobial biofilms is metabolic cross-talk
between organisms. Chemically mediated signaling in the form of quorum sensing (QS) may play
a potential role within these interactions, stimulating both positive and negative effects, potentially
giving C. albicans a fitness advantage within polymicrobial niches. The C. albicans QS molecule farnesol
has been shown to be an important regulatory molecule in biofilm formation [123], as well as being able
to decrease bacterial biofilm formation and potentiate antimicrobial therapy [124,125]. Interestingly,
although being able to inhibit Strepotococcus mutans biofilm formation at high concentrations (~200 µm),
farnesol has been shown to promote biofilm formation and micro-colony development of S. mutans
at lower concentrations (25–50 µm) [126]. Additionally, S. mutans is able to reduce the quantity of
farnesol produced in these dual-species environment, suggesting that this molecule plays a key role in
biofilm formation in oral plaque.
Throughout Candida biofilms, there is a heterogeneous oxygen gradient, which decreases steadily
from the top to the bottom of the biofilm architecture. Interspersed within the dense biofilm network
are hypoxic niches, creating small oxygen-deprived microenvironments. These micro-niches, have
been shown to support the growth of various anaerobic bacteria [127,128]. Fox and colleagues [128]
demonstrated that in the presence of biofilms containing C. albicans, various anaerobic gut microbiota
bacteria were able to survive in normoxic conditions that were typically toxic to the bacteria.
Reciprocally, they demonstrated that Clostridium perfringens was able to induce Candida biofilm
formation and also phenotypic switching from white to the opaque cell type through upregulation
of the transcriptional regulator WOR1. Another Clostridia species, C. difficile, has also been shown to
survive within the hypoxic microenvironments within C. albicans biofilms, yet conversely inhibited
hyphal formation. It instead induced the hyphae-yeast transition, through the molecule p-Cresol [127].
The diversity of the human microbiota coupled with the advancement in interest of the mycobiome
provides a platform for endless opportunities for interaction of different microbes. Through comparison
of the micro- and mycobiome in patients with Crohn’s disease (CD), it has been shown that specific
fungal-bacterial interactions associate with dysbiosis in CD [129]. The authors then identified a
correlation between the fungus C. tropicalis and the bacteria Serratia marcescens and E. coli. This was
then validated in vitro whereby they demonstrated the ability of these three organisms to form
triadic biofilms that promoted overall biomass and stimulated hyphal formation of C. tropicalis.
Though caution should be exercised in reliance of statistical relationships, as these approaches lead to
the exclusion of perceived bystander microorganisms that may have greater functional importance
than are currently considered.
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7. What Drives Biofilm Heterogeneity?
Through experimental advancement and use of more sophisticated technologies, Candida biofilm
ECM has been extensively analysed [130–133]. Compositionally, the ECM is comprised of four main
macromolecular constituents: proteins, carbohydrates, lipids, and nucleic acid. However, through use
of a multi-omics approach, Zarnowksi et al. (2014) identified an abundance of novel components within
these four subclasses, generating a distinguished compendium of its constituents. This demonstrated
its clinical relevance of providing biofilm stability, sequestration of drugs, and protection from the
surrounding environmental stressors, as well as subsequently facilitating biofilm dispersal [130].
While the majority of ECM-mediated research has focused on the role of polysaccharides, another
notable component is eDNA [134]. Despite only contributing to 5% of the ECM, eDNA plays a
substantial role in maintaining structural homeostasis within the matrix. It is thought to act as
molecular glue, facilitating cohesion between the other matrix constituents. Exogenous addition and
enzymatic depletion of eDNA have been shown to both positively and negatively influence biofilm
formation, respectively [134]. Additionally, the addition of DNase to amphotericin B and caspofungin
enhances their activity against sessile communities, however, no positive interaction is observed with
azoles [135]. Interestingly, eDNA is also factor that contributes for the biofilm forming heterogeneity
observed between LBF and HBF. Significantly increased quantities of eDNA were released from both
early and mature biofilms of HBF compared to LBF [136]. Given that HBF are more resistant to
amphotericin B (AMB) than LBF [19], the combination therapy with AMB and DNase, which sensitises
HBF up to eight-fold compared to AMB alone, is very much a matrix-mediated resistance [136].
The role of the other ECM components within biofilm heterogeneity observed in clinical isolates
remains unknown, yet given the differences observed between azole and echinocandin susceptibility
of these isolates [14], it is highly likely that key components are involved and worthy of further scrutiny
to determine if strain specific ECM motifs are present.
Given the complexity of the biofilm formation process, it is unsurprising that a variety
of transcriptional regulations determine this process. Central to this is the master regulatory
transcriptional network as defined by Nobile and collegues (2012) [137]. Originally, a hub of
six regulatory genes (TEC1, NDT80, ROB1, BRG1, BCR1, EFG1) was identified that regulate both
themselves and approximately 1000 genes involved in processes biofilm formation such as hyphal
morphogenesis, ECM production, and drug resistance [137]. Furthermore, this same group then
identified an additional three regulatory genes responding to temporal changes in biofilm formation.
Using deletion strains, they identified FLO8 as a regulator throughout all stages of development, from
initial adherence to fully mature biofilms, whereas RFX2 and GAL4 are required only in the later
stages of maturation [138]. Interestingly, when comparative transcriptomes between C. albicans and
C. parapsilosis biofilms were analysed, they contained a distinct variation between the two species.
A large transcription factor deletion screening identified eight biofilm regulators in C. parapsilosis.
Of the regulatory network of C. parapsilosis, only EFG1 and BCR1 are also involved within the
categorised C. albicans network [139]. While these approaches provide invaluable insights into the
transcriptional mechanisms underpinning biofilm development, their limitations lie within only
considering laboratory reference strains. Indeed, when the transcriptional profile of a group of
C. albicans LBF and HBF were compared, no transcriptional differences of two of the master biofilm
regulators (BCR1 and EFG1) was shown, despite the phenotypic and biological differences between
the strain subsets [19].
As well as a defined transcriptional network governing biofilm formation, various metabolic
circuits control the transition from planktonic cells to biofilm maturity. Using a metabolomics
approach, Zhu and colleagues (2013), performed a time-course analysis of the metabolome of C. albicans
biofilms through development [140]. They identified 31 metabolites that were differently expressed
between planktonic and biofilm cells that were involved in various processes, including the TCA cycle,
amino acid biosynthesis, and oxidative stress. Interestingly, they showed that trehalose was highly
up-regulated after 6 h of maturation. Using a TPS1 knockout, they demonstrated an impaired biofilm
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phenotype, as well as increased sensitivity to amphotericin B and miconazole, thus highlighting the
importance of the trehalose biosynthesis pathway for biofilm maturation [140].
In order to better our understanding of the molecular mechanisms facilitating biofilm
heterogeneity between C. albicans clinical isolates, Rajendran and colleagues (2016) undertook a
transcriptional profiling approach [64]. As expected, well-known biofilm-related genes such as HWP1
and ALS3 were up-regulated in HBF. A non-biased computational approach was further utilized, and in
doing so, a metabolic circuitry to defined biofilm phenotypes was established (Figure 4). Using KEGG
pathway analysis, it was shown that the amino acid pathways arginine and proline metabolism,
pyruvate metabolism, and also fatty acid metabolism, were highly expressed in HBF. Within the
subnetwork of these pathways, the gene encoding aspartate aminotransferase (AAT1) was shown to be
a regulatory hub of these networks. Pharmacological inhibition of this enzyme was shown to perturb
biofilm formation, highlighting its potential as a target for biofilm-based infections.J. Fungi 2018, 4, 12 11 of 19 
 
 
Figure 4. Maximum scoring metabolic subnetwork in the LBF-HBF network. Differential 
transcriptional expression between LBF and HBF. Red gene names indicate upregulation in HBF, with 
blue indicating LBF. 
The adaptation of its metabolism is fundamental to the pathogenicity and survival of C. albicans 
within the host [141]. The immune response to Candida biofilms is diminished compared to planktonic 
cells [142], with further evidence suggesting the potential to stimulate biofilm production, resulting 
in an altered inflammatory output [143]. In response to a device-related C. albicans infection, the most 
responsive leukocyte was shown to be neutrophils [144]. These host cells are able to successfully 
phagocytose the yeast morphology of C. albicans, yet the larger hyphal morphologies require the 
release of neutrophil extracellular traps (NET) for effective phagocytosis [145]. However, C. albicans 
biofilms are able to inhibit the release of NET during biofilm formation through the production of 
ECM [146]. This is unlike C. glabrata biofilms, whereby a degree of NET are released, although not 
comparable to NET release against planktonic cells [147]. The differences between these organisms is 
likely to be the biofilm architecture, predominantly the ECM composition. Despite Candida biofilms 
being more resistant to host defenses, the addition of antifungals has been shown synergise and 
increase the susceptibility of these communities [148]. This combinatory effect was shown for 
anidulafungin but not voriconazole, and has also been shown to be active against C. parapsilosis 
biofilms [149]. Furthermore, the addition of the antifungal resulted in increased release of tumor 
necrosis factor α (TNF-α) compared to untreated biofilms [148]. Interestingly, this same cytokine has 
been shown to block C. albicans biofilm formation through interaction with a major carbohydrate 
component of the fungal cell wall [150]. 
The presence of additional environmental stressors such as pH, thermal and oxidative stress, 
and also the availability of nutrients results in the metabolic adaptation of the biofilm to acclimatize 
to its surroundings. This, combined with inter-relationships with other yeasts and bacteria, creates 
multiple permutations of strain specific biofilms, all exhibiting their distinct and unique fingerprints. 
  
i r 4. Maximu scoring metabolic subnetwork in the LBF-HBF network. Differential transcription l
expression between LBF and HBF. Red gene names indicate upregulation in HBF, with blue
indicating LBF.
The adaptation of its metabolism is fundamental to the pathogenicity and survival of C. albicans
within the host [141]. The immune response to Candida biofilms is diminished compared to planktonic
cells [142], with further evidence suggesting the potential to stimulate biofilm production, resulting in
an altered inflammatory output [143]. In response to a device-related C. albicans infection, the most
responsive leukocyte was shown to be neutrophils [144]. These host cells are able to successfully
phagocytose the yeast morphology of C. albicans, yet the larger hyphal morphologies require the release
of neutrophil extracellular traps (NET) for effective phagocytosis [145]. However, C. albicans biofilms
are able to inhibit the release of NET during biofilm formation through the production of ECM [146].
This is unlike C. glabrata biofilms, whereby a degree of NET are released, although not comparable
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to NET release against planktonic cells [147]. The differences between these organisms is likely to
be the biofilm architecture, predominantly the ECM composition. Despite Candida biofilms being
more resistant to host defenses, the addition of antifungals has been shown synergise and increase
the susceptibility of these communities [148]. This combinatory effect was shown for anidulafungin
but not voriconazole, and has also been shown to be active against C. parapsilosis biofilms [149].
Furthermore, the addition of the antifungal resulted in increased release of tumor necrosis factor α
(TNF-α) compared to untreated biofilms [148]. Interestingly, this same cytokine has been shown to
block C. albicans biofilm formation through interaction with a major carbohydrate component of the
fungal cell wall [150].
The presence of additional environmental stressors such as pH, thermal and oxidative stress, and
also the availability of nutrients results in the metabolic adaptation of the biofilm to acclimatize to its
surroundings. This, combined with inter-relationships with other yeasts and bacteria, creates multiple
permutations of strain specific biofilms, all exhibiting their distinct and unique fingerprints.
8. Conclusions and Future Outlook
Extensive studies with laboratory strains have facilitated greater understanding of the biofilm.
Underpinning the rationale for these studies, however, is the clinical importance of Candida biofilms
in human health, and the drive to discover new therapeutic targets. Therefore, reliance on arguably
artificial strains to guide our therapeutic search limits our potential. We have presented some ideas
supported by recent data to provoke consideration and benefit from working with clinical isolates.
Understanding how real strains perform under real clinical conditions can only support and enhance
our understanding, whether at a phenotypic or genotypic level. Enhanced or diminished biofilm
phenotypes may provide a rationale way to develop new anti-biofilm therapies.
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